164 related articles for article (PubMed ID: 17037376)
21. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
[TBL] [Abstract][Full Text] [Related]
22. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
23. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
Lockwood DN; Cunha Mda G
Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
[No Abstract] [Full Text] [Related]
24. Dapsone drug resistance in the MDT era.
Roche PW; Neupane KD; Failbus SS; Butlin CR
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
[No Abstract] [Full Text] [Related]
25. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months.
Ji B
Lepr Rev; 1998 Jun; 69(2):106-9. PubMed ID: 9715593
[No Abstract] [Full Text] [Related]
26. [Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlândia].
Goulart IM; Arbex GL; Carneiro MH; Rodrigues MS; Gadia R
Rev Soc Bras Med Trop; 2002; 35(5):453-60. PubMed ID: 12621663
[TBL] [Abstract][Full Text] [Related]
27. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
[TBL] [Abstract][Full Text] [Related]
28. MDT-MB therapy in paucibacillary leprosy: a clinicopathological assessment.
Prasad PV; Babu A; Kaviarasan PK; Viswanathan P; Tippoo R
Indian J Dermatol Venereol Leprol; 2005; 71(4):242-5. PubMed ID: 16394431
[TBL] [Abstract][Full Text] [Related]
29. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Deps P; Guerra P; Nasser S; Simon M
Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
[TBL] [Abstract][Full Text] [Related]
30. Study of multidrug therapy in paucibacillary leprosy.
Kar PK; Sohi AS
J Indian Med Assoc; 1989 Feb; 87(2):34-6. PubMed ID: 2674283
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
[TBL] [Abstract][Full Text] [Related]
33. Delayed resolution versus treatment failure in paucibacillary leprosy patients under six months fixed duration multidrug therapy.
Job CK; Jayakumar J; Aschhoff M
Indian J Lepr; 1997; 69(2):131-42. PubMed ID: 9290964
[TBL] [Abstract][Full Text] [Related]
34. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
Mane I; Cartel JL; Grosset JH
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
[TBL] [Abstract][Full Text] [Related]
35. Treatment of leprosy.
Kar HK; Gupta R
Clin Dermatol; 2015; 33(1):55-65. PubMed ID: 25432811
[TBL] [Abstract][Full Text] [Related]
36. Three years assessment of multidrug therapy in multibacillary leprosy cases.
Ganapati R; Revankar CR; Pai RR
Indian J Lepr; 1987; 59(1):44-9. PubMed ID: 3611860
[TBL] [Abstract][Full Text] [Related]
37. [Chemotherapy of Hansen's disease in Japan--present status].
Goto M; Miyagi S; Takizawa H; Kitajima S
Nihon Hansenbyo Gakkai Zasshi; 1998 Jul; 67(2):305-11. PubMed ID: 9785846
[TBL] [Abstract][Full Text] [Related]
38. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
[TBL] [Abstract][Full Text] [Related]
39. Combined regimens of one year duration in the treatment of multibacillary leprosy--I. Combined regimens with rifampicin administered during one year.
Pattyn SR; Bourland J; Grillone S; Groenen G; Ghys P
Lepr Rev; 1989 Jun; 60(2):109-17. PubMed ID: 2671559
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
